Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  Probi AB (publ)    PROB   SE0001280355

PROBI AB (PUBL)

(PROB)
  Report
Delayed Quote. Delayed NASDAQ OMX STOCKHOLM - 10/30 07:59:46 am
387.5 SEK   +8.39%
10/21Q3 2020 : Strong growth with good profitability
AQ
10/20PROBI : acquires shares in Vital Nutrients Holdings and enters into strategic partnership
AQ
10/19PROBI : Presentation of Probi's Q3 report
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Probi : New clinical results on stress from Probi and their probiotic strain L. plantarum, HEAL9

share with twitter share with LinkedIn share with facebook
08/27/2020 | 10:01am EDT

Randomized, double blind, placebo-controlled clinical study published. The trial showed significant reduction in the pro-inflammatory markers fractalkine and CD163.

Maintaining or improving mental health and function is of growing interest for many people, and the number of chronically stressed people is increasing dramatically. Mental health is an area which is addressed by the World Health Organization (WHO)*, as it has great impact on individuals as well as on our society in general.

Probiotics may play a role for psychological function, as the intestine and the brain are connected via the gut-brain axis. Furthermore, the intestinal microbiota influences the immune activation and signaling molecules that are involved in the stress response.

During acute stress the immune system is activated, leading to an imbalance between inflammatory and anti-inflammatory responses. In chronic stress this imbalance and resulting low-grade inflammation may lead to development of diversified stress-related diseases such as cardiovascular diseases, neurodegenerative diseases and cancer.

"The aim of the study was to investigate if intake of the probiotic strain Lactiplantibacillus plantarum, HEAL9[TM] could counteract elevated cortisol and inflammation levels in subjects with chronic stress that are exposed to an acute stress test", explains Titti Niskanen, Director R&D & Clinical Operations.

"We are pleased with the clinical results showing that intake of Lactiplantibacillus plantarum, HEAL9[TM] resulted in significantly decreased plasma levels of the two inflammatory markers (soluble fractalkine and CD163) compared to placebo - these markers are coupled to acute stress in chronically stressed individuals", Niskanen concludes. It is, to our knowledge, the first time it has been shown that acute mental stress triggers the immediate release of soluble fractalkine but also that a probiotic intervention can reduce the release and thereby potentially mitigate the negative physiological side effects of stress.

Tom Rönnlund, CEO at Probi emphasizes the clinical importance of probiotics and mental health: "We are very excited about the study results with HEAL9[TM]", and he continues: "Probi believes that probiotics can play a part in mental health and improve the well-being of many people. This exploratory study provides us with a good platform for further investigations within the gut-brain axis area".

The clinical trial, published in Physiology & Behavior, can be found here (https://doi.org/10.1016/j.physbeh.2020.113083).

 

FOR FURTHER INFORMATION, CONTACT:

Charlotte Beyerholm, Director Marketing & Global Communication, Probi[®], tel +46 76 870 94 65, e-mail: charlotte.beyerholm@probi.com
Titti Niskanen, Director R&D & Clinical Operations, Probi, tel +46 46 286 89 68, e-mail: titti.niskanen@probi.com
Tom Rönnlund, CEO, Probi[®], tel +46 46 286 89 40, e-mail: trd@probi.com

 

ABOUT PROBI

Probi is a world leader within probiotics. Our vision is to help people live healthier lives by delivering effective and well-documented probiotics, with proven health benefits based on scientific research. Probi offers dedicated probiotic expertise and partnership all the way from R&D to finished products for companies within the consumer healthcare and food industry. Our GMP certified manufacturing facilities produce probiotics in custom made formats with value-adding delivery technologies. Founded by scientists in Sweden 1991, Probi is a multinational company with 4 centers of excellence, active in more than 40 markets around the world and holding over 400 patents worldwide. Read more at www.probi.com.

* Reference: https://www.who.int/mental_health/evidence/en/Note: Lactiplantibacillus plantarum was formerly named Lactobacillus plantarum, prior to the taxonomic reclassification.

 

[image]  

https://news.cision.com/probi/r/new-clinical-results-on-stress-from-probi-and-their-probiotic-strain-l--plantarum--heal9-tm--,c3182604

https://mb.cision.com/Main/1556/3182604/1298420.pdf

https://news.cision.com/probi/i/gettyimages-1188480338-stress-publication,c2818055

(c) 2020 Cision. All rights reserved., source Press Releases - English


Stocks mentioned in the article
ChangeLast1st jan.
PROBI AB (PUBL) 8.39% 387.5 Delayed Quote.61.04%
SYMRISE AG -1.03% 105.85 Delayed Quote.12.85%
share with twitter share with LinkedIn share with facebook
All news about PROBI AB (PUBL)
10/21Q3 2020 : Strong growth with good profitability
AQ
10/20PROBI : acquires shares in Vital Nutrients Holdings and enters into strategic pa..
AQ
10/19PROBI : Presentation of Probi's Q3 report
AQ
08/27PROBI : New clinical results on stress from Probi and their probiotic strain L. ..
AQ
07/17Q2 2020 : Probi raises long-term financial targets
AQ
07/14PROBI PUBL : Presentation of Probi's Q2 report 2020 and new financial targets
PU
07/14PROBI PUBL : Presentation of Probi's Q2 report 2020 and new financial targets
AQ
07/02PROBI PUBL : and Örebro University to collaborate on research into exploration o..
AQ
05/14PROBI PUBL : A true pioneer in probiotic research is elected NutraChampion 2020
AQ
05/14PROBI AB (PUBL) : Ex-dividend day for final dividend
FA
More news
Financials
Sales 2020 713 M 80,2 M 80,2 M
Net income 2020 103 M 11,6 M 11,6 M
Net cash 2020 261 M 29,3 M 29,3 M
P/E ratio 2020 42,8x
Yield 2020 0,41%
Capitalization 4 415 M 497 M 497 M
EV / Sales 2020 5,83x
EV / Sales 2021 5,28x
Nbr of Employees -
Free-Float 38,9%
Chart PROBI AB (PUBL)
Duration : Period :
Probi AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PROBI AB (PUBL)
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
 
Mean consensus -
Number of Analysts 2
Average target price 440,00 SEK
Last Close Price 387,50 SEK
Spread / Highest target 13,5%
Spread / Average Target 13,5%
Spread / Lowest Target 13,5%
EPS Revisions
Managers
NameTitle
Tom Juhani Rönnlund Chief Executive Officer
Jean-Yves Parisot Chairman
Andy McShea Vice President-Operations
Henrik Lundkvist Chief Financial Officer
Niklas Brandt Vice President-Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
PROBI AB (PUBL)61.04%456
BY-HEALTH CO., LTD.58.81%6 007
BALCHEM CORPORATION-1.65%3 243
THE SIMPLY GOOD FOODS COMPANY-34.13%1 796
MEDIFAST, INC.28.21%1 766
JAMIESON WELLNESS INC.50.68%1 153